Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

BACKGROUND: Approximately half of tumor cell lines are resistant to the tumor-selective apoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand (Apo22L/TRAIL). Previously, we showed that combining Apo2L/TRAIL with sorafenib, a multikinase inhibitor, results in dramatic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulghani, Junaid, Allen, Joshua E., Dicker, David T., Liu, Yingqiu Yvette, Goldenberg, David, Smith, Charles D., Humphreys, Robin, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784419/
https://www.ncbi.nlm.nih.gov/pubmed/24086526
http://dx.doi.org/10.1371/journal.pone.0075414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784419/
https://www.ncbi.nlm.nih.gov/pubmed/24086526
http://dx.doi.org/10.1371/journal.pone.0075414

Ejemplares similares